Search

Your search keyword '"MALUCCHI, S"' showing total 1 results
Start Over Author "MALUCCHI, S" Journal european journal of neurology

Refine your results

1 results on '"MALUCCHI, S"'

1. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.

Author

Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, Sperli F, and Bertolotto A

Subjects
Adult, Female, Fingolimod Hydrochloride administration & dosage, Follow-Up Studies, Humans, Immunologic Factors administration & dosage, Immunosuppressive Agents administration & dosage, Male, Natalizumab administration & dosage, Recurrence, Retrospective Studies, Fingolimod Hydrochloride pharmacology, Immunologic Factors pharmacology, Immunosuppressive Agents pharmacology, Multiple Sclerosis, Relapsing-Remitting drug therapy, Natalizumab pharmacology, Outcome Assessment, Health Care
Abstract

Background and Purpose: Natalizumab discontinuation induces the recurrence of multiple sclerosis disease activity: currently no therapeutic approach has been found able to abolish disease reactivation., Methods: The recurrence of disease activity after natalizumab discontinuation was retrospectively evaluated in 79 patients who had been treated with immunomodulating agents, other first-line therapies, fingolimod or not treated., Results: No differences have been found in clinical or magnetic resonance imaging recurrence of disease activity amongst the groups. Interestingly, no disease reactivation was observed only in one patient treated for 6 months with monthly pulses of cyclophosphamide., Conclusion: Disease modifying treatment or 'no treatment' is unable to abolish disease activity reactivation after natalizumab discontinuation., (© 2014 The Author(s) European Journal of Neurology © 2014 EAN.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results